1 2 9 5 b r i e f c o m m u n i c at i o n s
b r i e f c o m m u n i c at i o n s Over 160 million individuals are infected with HCV, and, in ~80% of cases, infection persists and can lead to severe liver disease. No vaccine is available, and current treatments are not effective against the strains most prevalent in the US and Europe. After the virus enters liver cells, a viral polyprotein is translated in the endoplasmic reticulum (ER) from a single positive-stranded RNA genome and processed into structural and nonstructural proteins 1 . Nonstructural proteins autonomously replicate viral RNA, which, together with the structural proteins, the nucleocapsid core and the E1 and E2 envelope proteins, is packaged into progeny virions. Both RNA replication and infectious particle assembly are thought to occur at ER membranes. However, recent reports showed a crucial involvement of lipid droplets in infectious virion production [2] [3] [4] , and viral budding requires the lipoprotein secretion pathway [5] [6] [7] .
Lipid droplets form when triglycerides and cholesterol esters accumulate between the bilayer of the ER membrane and are surrounded by a phospholipid monolayer and associated proteins 8 . DGAT1 and DGAT2 enzymes catalyze the final step in triglyceride biosynthesis and are essential in lipid droplet biogenesis 9 . Both enzymes are ER resident, and upon cellular uptake of fatty acids, DGAT2, but not DGAT1, localizes to lipid droplets 9 . Both enzymes have similar activities in vitro; however, DGAT1 has broader substrate specificity 9 , and only DGAT2 is essential in vivo 10, 11 .
To determine whether DGAT enzymes influence the HCV life cycle, we introduced shRNAs directed against DGAT1 or DGAT2 into HCV-permissive hepatoma cells [12] [13] [14] (Supplementary Methods) .
We inoculated shRNA-transduced cultures with low concentrations of infectious HCV-Jcl, a partially cell culture-adapted molecular clone of HCV, expressing EGFP as a marker for infection (EGFP-Jc1) and monitored viral spread by flow cytometry. Spreading infection was suppressed by 65-90% with two DGAT1 shRNAs (day 9 after infection) ( Fig. 1a) . Expression of shRNA-resistant DGAT1 rescued the suppressive effect of the DGAT1 knockdown on viral infection ( Supplementary Fig. 1 ). We saw no change with DGAT2-targeting shRNA, pointing to a unique role of DGAT1 in HCV infection. We verified knockdown of DGAT expression by real-time RT-PCR and, for DGAT1, by western blotting (Fig. 1b) .
We obtained similar results in infected hepatoma cells treated with a DGAT1-specific small molecule inhibitor (further described in Supplementary Fig. 2 ). Increasing concentrations of DGAT1 inhibitor caused a gradual decline in infectious viral particle production for infectious HCV-Jc1 and the parental HCV-JFH1 (each expressing firefly luciferase as infection marker) ( Fig. 1c ; half-maximal inhibitory concentration of Luc-Jc1 = 7.3 μM; Luc-JFH1 = 7.4 μM). We also performed experiments with the DGAT1 inhibitor in freshly isolated primary human hepatocytes 15 . We inoculated cells with infectious HCV-Jc1 and measured focus-forming units after transfer of infectious supernatant from primary cells to permissive hepatoma cells. Primary hepatocytes were effectively infected and produced viral titers similar to hepatoma cells ( Supplementary Fig. 3a,b ). Production of infectious viral particles was suppressed by DGAT1 inhibitor treatment, albeit at higher concentrations than in hepatoma cells ( Fig. 1d) . These data show that DGAT1 activity is necessary for efficient propagation of HCV in transformed and primary human liver cells.
To identify which step in the HCV life cycle requires DGAT1, we quantified intracellular and secreted HCV RNA in infected hepatoma cells. Treatment with the DGAT1 inhibitor reduced viral RNA released into the culture supernatant by ~80%, whereas intracellular viral RNA concentrations remained unchanged ( Fig. 1e and Supplementary  Fig. 3c ). We observed no change in intracellular viral protein expression ( Fig. 1f) . Thus, DGAT1 activity is not required for viral RNA replication and translation but probably controls HCV infection at the level of virion assembly or release.
To differentiate between these possibilities, we isolated viral particles from infected cells and used them to inoculate naive cells. Intracellular infectivity was lower in DGAT1 inhibitor-treated cultures (60%) compared to vehicle-treated cells, indicating that viral assembly is the step in the viral life cycle regulated by DGAT1, although additional effects on viral release cannot be excluded ( Fig. 1g) .
Because lipid droplets are crucial in HCV assembly, we speculated that loss of DGAT1 activity reduces cellular lipid droplet levels and thereby causes the reduction in infectious particle production. Unexpectedly, Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1
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Hepatitis C virus (HCV) infection is closely tied to the lipid metabolism of liver cells. Here we identify the triglyceridesynthesizing enzyme diacylglycerol acyltransferase-1 (DGAT1) as a key host factor for HCV infection. DGAT1 interacts with the viral nucleocapsid core and is required for the trafficking of core to lipid droplets. Inhibition of DGAT1 activity or RNAi-mediated knockdown of DGAT1 severely impairs infectious virion production, implicating DGAT1 as a new target for antiviral therapy.
b r i e f c o m m u n i c at i o n s we observed no change in overall neutral lipid content, lipid droplet size or lipid droplet numbers in DGAT1 inhibitor-treated hepatoma cells ( Fig. 1h) . Indeed, concentrations of triglycerides, cholesterol esters, phospholipids and secreted lipoproteins remained unchanged in cells treated with the DGAT1 inhibitor or shRNAs against DGAT1 or DGAT2, whereas knockdown of both DGAT enzymes together efficiently reduced neutral lipid content and lipid droplet numbers (Supplementary Fig. 4) . These results show that the two DGAT enzymes have redundant functions in lipid synthesis in hepatoma cells and that a more complex mechanism than the mere reduction of lipid droplets is responsible for the inhibitory effect on HCV infection.
We focused our efforts on the viral core protein because it localizes to lipid droplets, and this localization has a major role in HCV particle assembly 2,4,16 . The core protein represents the first 191 amino acids of the viral polyprotein and anchors the polyprotein at the ER membrane with its C-terminal signal peptide 17 . After two sequential C-terminal cleavages, the processed core remains attached to the cytoplasmic leaflet of the ER membrane and from there gains access to the surface of lipid droplets 18 .
To determine whether DGAT1 regulates core association with lipid droplets, we isolated the lipid droplet fraction from infected cells. The core protein was present in the lipid droplet fraction isolated from control-treated, but not DGAT1 inhibitor-treated, cells, demonstrating that core association with lipid droplets depends on DGAT1 (Fig. 1i) . We obtained similar results with the viral NS3 protein, which, together with the core protein, localizes to lipid droplets during active HCV particle production ( Fig. 1i) 2, 19 . The lipid droplet fractions contained similar amounts of the lipid droplet-resident adipose differentiation-related protein, whereas the ER-resident proteins calreticulin and binding immunoglobulin protein (BiP) were absent (Fig. 1i) .
Immunofluorescence microscopy confirmed that the core protein was retained at the ER in hepatoma cells treated with the DGAT1 inhibitor or expressing shRNAs against DGAT1, but not DGAT2 (Supplementary Fig. 5a,c) . In contrast, overexpression of DGAT1 in HeLa cells, which harbor very few lipid droplets, was sufficient to induce the localization of the core protein from the ER to lipid droplets, a process reversible by the addition of the DGAT1 inhibitor (Supplementary Fig. 6) .
Because the localization of the core protein to lipid droplets is essential for recruiting viral RNA replication proximal to lipid droplets 2 , we stained HCV-infected cells with antibodies detecting viral doublestranded (ds) RNA 20 . Although in vehicle-treated cells a subset of lipid droplets was decorated with signals for dsRNAs, there was very little overlap between lipid droplet-and dsRNA-generated signals in DGAT1 inhibitor-treated cells (Fig. 1j) . These results support the model that packaging of viral genomes into progeny virions requires DGAT1.
To study the molecular mechanism of how DGAT1 regulates core trafficking to lipid droplets, we performed coimmunoprecipitation experiments. The core protein associated with Flag-Dgat1, but not Flag-Dgat2, after coexpression in 293T cells; this interaction was not interrupted by the DGAT1 inhibitor ( Fig. 2a) . In addition, the core protein efficiently immunoprecipitated with catalytically inactive Dgat1 (H426A), indicating that the interaction does not require the enzymatic activity of DGAT1 (Supplementary Fig. 7) . The core protein also immunoprecipitated with endogenous DGAT1 after lentiviral expression in hepatoma cells ( Fig. 2b) and in two permissive hepatoma cell lines infected with HCV-Jc1 (Fig. 2c) . However, despite the protein-protein interaction, we observed no marked colocalization of the proteins by immunofluorescence microscopy (Fig. 2d) . Endogenous DGAT1 showed a reticular localization, whereas the core protein mainly localized to punctate structures corresponding to lipid droplets (Fig. 2d) . After core protein expression, DGAT1 appeared more concentrated around lipid droplets carrying core protein, but we observed no substantial overlap (Fig. 2d) . Notably, treatment with DGAT1 inhibitor or knockdown of DGAT2 did not affect the subcellular localization of DGAT1 ( Supplementary Fig. 5b,d) .
We speculated that the core protein only transiently interacts with DGAT1 when produced at the ER before migrating to lipid droplets and therefore examined a core mutant (SPMT) that cannot be processed and therefore cannot gain access to lipid droplets 18 . The SPMT mutant colocalized with endogenous DGAT1, supporting the idea that both proteins interact at the ER (Fig. 2d) . In agreement with this model, Flag-Dgat1 interacted more strongly with the ER-retained SPMT mutant than with wild-type core protein in coimmunoprecipitation experiments ( Fig. 2e) . A truncated core mutant lacking the C-terminal signal peptide (core 1-173) coimmunoprecipitated with Dgat1, showing that this region does not mediate the interaction (Fig. 2e) .
Collectively, our data suggest a hitherto unrecognized function of DGAT1 as a host factor for HCV infection. They demonstrate that infectious HCV particle production does not randomly occur in the vicinity of lipid droplets but requires DGAT1-mediated lipid droplet formation. DGAT1 binds the HCV core protein and localizes core protein to DGAT1-generated lipid droplets, thereby recruiting viral RNA replication complexes to the proper site of viral assembly (Fig. 2f) . In cells treated with the DGAT1 inhibitor, the core protein still interacts with DGAT1 but cannot access lipid droplets. As a consequence, (e) Coimmunoprecipitation assays in 293T cells transfected with expression vectors for wild-type (WT), mutant (SPMT) or truncated (1-173) core protein and the Flag-Dgat1-expressing plasmid. Arrows mark unprocessed (top) and processed (bottom) core protein. (f) Model of HCV core recruitment to DGAT1-generated lipid droplets. The HCV core protein interacts with DGAT1 at the ER and thereby gains access to DGAT1-generated lipid droplets. This step is crucial to recruit HCV RNA replication complexes to ER membranes in the vicinity of lipid droplets and to initiate assembly of progeny virions. When the formation of DGAT1generated lipid droplets is prevented by the treatment with the DGAT1 inhibitor, the translocation of the HCV core protein to lipid droplets is disrupted, and infectious HCV particles cannot form, despite the presence of DGAT2-generated droplets.
b r i e f c o m m u n i c at i o n s production of infectious viral particles is impaired despite the presence of lipid droplets generated by DGAT2.
Why HCV selectively targets DGAT1, and not DGAT2, remains unknown at this point. However, the finding that DGAT2-generated lipid droplets form normally in DGAT1 inhibitor-treated cells points to a unique opportunity for therapeutic intervention. DGAT1 inhibitors, currently in early clinical trials for obesity-associated diseases, may serve as unique antiviral therapeutics that selectively suppress HCV's interaction with lipid droplets without compromising the overall formation of lipid droplets in liver cells.
Note: Supplementary information is available on the Nature Medicine website.
